Trimetazidine is a piperazine derivative indicated as an adjunct therapy in symptomatic treatment of stable angina pectoris. Trimetazidine is described as the first cytoprotective anti-ischemic agent. Trimetazidine is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves myocardial glucose utilization through inhibition of fatty acid metabolism. Synthink is a most trusted source of Trimetazidine Degradation Impurity, Trimetazidine Genotoxic impurity, Trimetazidine Process Impurity, USP related compound, Trimetazidine Nitrosamine impurity, N-Nitroso impurity etc. which are listed on this page.